FY2025 EPS Estimates for Opthea Boosted by Leerink Partnrs

Opthea Limited (NASDAQ:OPT - Free Report) - Analysts at Leerink Partnrs upped their FY2025 earnings estimates for shares of Opthea in a research note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn ($1.15) per share for the year, up from their prior estimate of ($1.20). The consensus estimate for Opthea's current full-year earnings is ($1.40) per share. Leerink Partnrs also issued estimates for Opthea's FY2026 earnings at ($1.05) EPS, FY2027 earnings at $0.15 EPS and FY2028 earnings at $1.60 EPS.

Separately, HC Wainwright dropped their target price on Opthea from $14.00 to $12.00 and set a "buy" rating on the stock in a research report on Tuesday, September 3rd.

Opthea Stock Performance

Shares of OPT traded down $0.04 during midday trading on Friday, hitting $4.99. The stock had a trading volume of 5,135 shares, compared to its average volume of 23,987. The company has a 50 day simple moving average of $3.61 and a two-hundred day simple moving average of $3.06. Opthea has a twelve month low of $1.60 and a twelve month high of $5.45.

About Opthea

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.